Faeth Therapeutics, Inc. Retained Earnings
Faeth Therapeutics, Inc. (FTH) had Retained Earnings of -$469.38 million as of 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:RetainedEarningsAccumulatedDeficit · last filed 2026-08-04
- 2026-06-30: Retained Earnings (Accumulated Deficit) -$469.38M.
- 2026-03-31: Retained Earnings (Accumulated Deficit) -$453.37M.
- 2025-12-31: Retained Earnings (Accumulated Deficit) -$283.14M.
- 2025-09-30: Retained Earnings (Accumulated Deficit) -$278.42M.
| Period end | Retained Earnings (Accumulated Deficit) |
|---|---|
| 2026-06-30 | -$469.38M 10-Q · filed 2026-08-04 |
| 2026-03-31 | -$453.37M 10-Q · filed 2026-05-15 |
| 2025-12-31 | -$283.14M 10-Q · filed 2026-08-04 |
| 2025-09-30 | -$278.42M 10-Q · filed 2025-11-14 |
| 2025-06-30 | -$273.85M 10-Q · filed 2025-08-05 |
| 2025-03-31 | -$268.92M 10-Q · filed 2025-05-06 |
| 2024-12-31 | -$262.05M 10-K · filed 2026-03-30 |
| 2024-09-30 | -$254.28M 10-Q · filed 2024-11-14 |
| 2024-06-30 | -$247.03M 10-Q · filed 2024-08-06 |
| 2024-03-31 | -$239.89M 10-Q · filed 2024-05-09 |
| 2023-12-31 | -$231.90M 10-K · filed 2025-03-28 |
| 2023-09-30 | -$224.48M 10-Q · filed 2023-11-07 |
| 2023-06-30 | -$217.36M 10-Q · filed 2023-08-03 |
| 2023-03-31 | -$207.97M 10-Q · filed 2023-05-09 |
| 2022-12-31 | -$197.79M 10-K · filed 2024-02-29 |
| 2022-09-30 | -$185.56M 10-Q · filed 2022-11-08 |
| 2022-06-30 | -$172.15M 10-Q · filed 2022-08-09 |
| 2022-03-31 | -$161.61M 10-Q · filed 2022-05-10 |
| 2021-12-31 | -$149.21M 10-K · filed 2023-03-29 |
| 2021-09-30 | -$139.84M 10-Q · filed 2021-11-10 |
| 2021-06-30 | -$130.16M 10-Q · filed 2021-08-11 |
| 2021-03-31 | -$120.38M 10-Q · filed 2021-05-13 |
| 2020-12-31 | -$112.41M 10-K · filed 2022-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |